Difficult-to-treat IBD is prevalent among approximately a quarter of individuals with IBD in a tertiary care setting.

Fostemsavir plus optimized background therapy was associated with improvements in immune biomarkers among HTE patients with MDR HIV infection.

The mRNA-1273 COVID-19 booster dose was safe and elicited robust immune responses among children aged 6 months to 5 years and 6 to 11 years.

Among cancer survivors, excess body weight is associated with an increased risk for a second primary malignant neoplasm.

Neuropathy and retinopathy are positively associated with moderate/severe periodontitis, according to a study published online.

Reduced AMR proportions were noted for multiple pathogens from 2007 to 2019, but some previously declining trends have reversed course since the COVID-19 pandemic.

The mortality rate in IBD, ranging from 1999 to 2020, remained stable until 2018 when rates began to increase until 2020.

The aTIV vaccine provides better protection against influenza-related medical encounters than the HD-TIV vaccine in high-risk older adults.